Alleged compliance failures at Omnicare lead to healthcare fraud lawsuit
By 
Jaclyn Jaeger2019-12-19T16:25:00
A series of alleged compliance failures at pharmaceutical services provider Omnicare has resulted in the Department of Justice intervening in yet another civil healthcare fraud lawsuit against the company.
Related articles
-
ArticleMost-trafficked content tells story of the compliance officer
Changes in the interests of our audience over the last several years help us to understand how much compliance officers must evolve in their jobs to meet the demands of a given time.
-
Blog
Omnicare to pay $28M to settle kickback allegations
Omnicare this week agreed to pay $28.1 million to resolve allegations that it solicited and received millions of dollars in kickbacks from drug maker Abbott Laboratories, the Justice Department announced. Jaclyn Jaeger has more.
-
Blog
Justice Department Intervenes in Whistleblower Suits Against Omnicare
The Justice Department recently intervened in two consolidated whistleblower lawsuits against drug company Omnicare over allegations that it solicited and received millions of dollars in kickbacks from drug maker Abbott Laboratories. “Although the U.S. Attorney’s Office for the Western District of Virginia is small, we will not waver in our ...
More from Regulatory Enforcement
-
PremiumDiscover, in allowing misclassification problem to fester, pushed compliance aside
Federal banking regulators have laid the blame for Discover Financial Services charging merchants $1 billion in excessive credit card fees over 17 years squarely at the feet of company executives.
-
News BriefCFPB drops $95M enforcement action against Navy Federal, without explanation
The Consumer Financial Protection Bureau has dropped a $95 million enforcement action against Navy Federal Credit Union, the latest regulatory pullback by the agency under President Donald Trump.
-
ArticleFCA drops ‘naming and shaming’ approach – except in ‘exceptional circumstances’
The UK’s financial regulator has had a rough ride over the past couple of years as its strategy to “name and shame” firms it opened investigations into was widely slammed by the industry and lawmakers over concerns that companies could be unfairly maligned.